Evolent Health (NYSE: EVH) announced its quarterly earnings on December 2, 2023, revealing earnings per share (EPS) of $0.08. This figure surpasses the consensus estimate of $0.06 by $0.02, according to FiscalAI. Despite the positive earnings report, the company is experiencing challenges, indicated by a negative net margin of 6.24% and a modest return on equity of 1.79%.
Market Performance and Stock Analysis
During trading hours on Tuesday, Evolent Health’s stock declined by $0.22, closing at $2.56. The trading volume reached 5,122,893 shares, significantly higher than the average volume of 2,931,346 shares. The company currently holds a market capitalization of approximately $285.14 million and has a price-to-earnings (P/E) ratio of -1.62, alongside a beta of 0.27.
Evolent Health’s financial ratios reveal further insights into its operations. It maintains a debt-to-equity ratio of 1.25, with both a quick and current ratio of 1.33. Over the past year, the company’s stock has fluctuated, with a 12-month low of $2.52 and a high of $12.06. Analysts have mixed sentiments about the stock, with recent ratings indicating a range of target prices.
Analysts’ Insights and Recommendations
Several research analysts have recently evaluated Evolent Health’s stock. Piper Sandler set a target price of $6.00 in a note issued on December 2. Conversely, BTIG Research lowered its price target from $16.00 to $10.00 while maintaining a “buy” rating. Truist Financial also adjusted its target price from $16.00 to $10.00, reaffirming its “buy” recommendation.
Citizens JMP followed suit, reducing its target from $11.00 to $10.00, while BMO Capital Markets initiated coverage with an “outperform” rating and a $7.00 target price. Overall, twelve analysts rate the stock as a Buy, while one gives it a Hold rating, and another rates it Sell. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $9.50.
Institutional Activity and Shareholder Dynamics
Recent trading activity indicates shifts in institutional investment in Evolent Health. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake by 2.9% in the first quarter, now holding 128,527 shares valued at approximately $1.22 million after acquiring an additional 3,572 shares. CIBC Private Wealth Group LLC notably raised its holdings by 4,000% in the third quarter, bringing its total ownership to 4,100 shares valued at about $35,000 following a purchase of 4,000 additional shares.
Other significant movements include Strs Ohio, which acquired a new position worth roughly $47,000 in the first quarter, and Headlands Technologies LLC, which also entered a new stake valued at about $58,000 during the second quarter. Osaic Holdings Inc. significantly increased its investment by 99.2% in the same quarter, now owning 11,119 shares valued at approximately $125,000 after adding 5,537 shares.
About Evolent Health
Founded in 2011, Evolent Health is headquartered in Arlington, Virginia. The company specializes in healthcare technology and services, collaborating with health systems, physician organizations, and health plans. Its core mission is to facilitate the transition from traditional fee-for-service payment models to innovative, value-based care arrangements.
Evolent Health leverages its proprietary technology platforms and clinical expertise to provide care management solutions, population health analytics, and clinical advisory services. As the healthcare landscape evolves, Evolent Health aims to remain at the forefront of enabling healthcare organizations to enhance care quality and operational efficiency.
